Table 2 Proportion of patients that had detectable antibodies, at different time points.

From: A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Strain

Weeks since symptom onset/infection

Asymptomatic

Mild symptoms

Severe symptoms

HCov-229E

3 weeks

20% (1 of 5)

100% (10 of 10)

 

MERS-CoV

13 weeks

 

67% (10 of 15)

95% (18 of 19)

 

26 weeks

 

67% (8 of 12)

100% (10 of 10)

 

52 weeks

 

67% (8 of 12)

100% (8 of 8)

  1. The time points were post symptom onset or infection, for HCoV-229E and MERS-CoV. The results for HCoV-229E are from Kraaijeveld et al.51, and report the number of individuals experiencing symptoms of a given severity that had significant antibody rises post infection. The results for MERS-CoV are taken across studies in which a cutoff for the assay being used was provided, and gives the number of patients for which IgG levels were above the respective cutoffs, at different time points (also see Fig. 3). For example, at week 26, there were 12 patients with mild symptoms from studies that reported a cutoff, and 8 of those patients had IgG levels above that cutoff. MERS-CoV data were digitized from six studies28,33,41,46,54,152.
Back to article page